ArticleJournal of nanobiotechnology2025
MIL-53(Fe)-Glucose self-assembled complex for enhanced angiogenesis and endothelial tip cell activation.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multimodal smart suture for dynamic postoperative wound monitoring.Bioactive materials · 2026Article
- Integrin β3 Promotes Retinal Neovascularization via Endoplasmic Reticulum Stress-Mediated Endothelial Cell Senescence.Investigative ophthalmology & visual science · 2026Article
- A temporally functional composite hydrogel scaffold for cranial defect repair via sequential modulation of angiogenesis and osteogenesis.Theranostics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Critical bone defects continue to pose a critical challenge in clinical settings. Facilitating rapid and thorough vascularization during bone regeneration is advantageous for the repair of substantial bone defects. Presently, the application of carriers to deliver pharmacological agents or growth factors to bone deficiency areas is an effective strategy for promoting vascularization within bone tissue, with the selection of appropriate carriers being of paramount importance. Because of its unique breathing characteristics and flexible framework structure, metal-organic framework (MOF) materials MIL-53(Fe), make promising nanocarrier for delivery applications. This work aimed to investigate the role of MIL-53(Fe) in the neovascularization of bone regeneration and the possible molecular mechanisms. The results validated that MIL-53(Fe) has excellent dispersion stability and biocompatibility. Angiogenic sprouting requires the activation of endothelial tip cells. By increasing the glycolytic activity of endothelial cells through self-assembling glucose, the nanocarrier MIL-53(Fe) markedly increased endothelial tip cell activation and boosted angiogenesis, ultimately encouraging bone repair. Through the Hippo/Yes-associated protein (YAP) pathway, the MIL-53(Fe)@Glucose complex was demonstrated to increase glycolytic activity and enhance activation of tip cell phenotype. This study demonstrated that the nanocarrier MIL-53(Fe) serves as an effective strategy for promoting rapid and sufficient angiogenesis during bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.